Pilot randomized controlled trial of a program to enhance experience and adherence with adjuvant endocrine therapy among women with non-metastatic breast cancer: 12-month quantitative results-Reference-Cited by-同舟云学术

Pilot randomized controlled trial of a program to enhance experience and adherence with adjuvant endocrine therapy among women with non-metastatic breast cancer: 12-month quantitative results

Published:2024-05-04 Issue: Volume: Page:
ISSN:1932-2259
Container-title:Journal of Cancer Survivorship
language:en
Short-container-title:J Cancer Surviv

Author:

Assan Odilon^ORCID,Memoli Victoria^ORCID,Guillaumie Laurence^ORCID,Turcotte Véronique^ORCID,Lemay Martine^ORCID,Dionne Anne^ORCID,Lemieux Julie^ORCID,Provencher Louise^ORCID,Gotay Carolyn^ORCID,de Bruin Marijn^ORCID,Guénette Line^ORCID,Lauzier Sophie^ORCID

Funder

Fonds d’enseignement et de recherche, Faculty of Pharmacy, Université Laval

Excellence Initiative of Aix-Marseille University - A*Midex

Aix-Marseille Institute of Public Health Sciences

Bourse de formation Desjardins pour la recherche et l’innovation de la Fondation du CHU de Québec-Université Laval

Canadian Institutes of Health Research

Fondation du CHU de Québec-Université Laval

Fonds de recherche du Québec–Santé (Québec Health Research Fund) in partnership with the Unité Soutien SRAP du Québec

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11764-024-01599-y.pdf

Reference52 articles.

1. Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, et al. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol. 2005;58:611–6. https://doi.org/10.1136/jcp.2004.022772.

2. Ma H, Lu Y, Marchbanks PA, Folger SG, Strom BL, McDonald JA, et al. Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women. Breast Cancer Res. 2013;15:R90. https://doi.org/10.1186/bcr3486.

3. Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, et al. Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019;37:423–38. https://doi.org/10.1200/JCO.18.01160.

4. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84. https://doi.org/10.1016/s0140-6736(11)60993-8.

5. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386:1341–52. https://doi.org/10.1016/s0140-6736(15)61074-1.